Company news

Cheng Du Sheng Nuo Biotec Co., Ltd. news in 2025

Cheng Du Sheng Nuo Biotec Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Announcement on Progress in Major Daily Operation Contracts of Wholly-owned Subsidiary

December 30, 2025

Announcement on Completing Term Change and Election of Board of Directors and Appointing Senior Management Members and Securities Affairs Representative

December 17, 2025

Announcement on Shareholding Reduction Results for Shareholders Holding Over 5% Shares, Partial Directors and Senior Management Members

December 14, 2025

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares to Below 5% and Reaching 1% Scale

December 10, 2025

Announcement on Voluntary Disclosure of Pentapeptide-18 Passing the New Cosmetic Ingredient Registration

December 3, 2025

Announcement on Election of Board of Directors at Expiry of Term of Office

December 1, 2025

Announcement on Shareholding Reduction Plan of Partial Directors and Senior Management Members

November 30, 2025

Announcement on Voluntary Disclosure of Notice on Listing Application Approval for Vepnadeptide Drug Substance

November 19, 2025

Announcement on Implementation of Interim Dividend Distribution for 2025

November 10, 2025

Announcement on Making Provisions for Asset Impairment for the First Three Quarters of 2025

October 27, 2025

Indicative Announcement on Shareholder Terminating Concerted Action Relationship and Equity Change Reaching 1% Scale

October 14, 2025

Announcement on Voluntary Disclosure of Earnings Preannouncement for the First Three Quarters of 2025

October 13, 2025

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

September 17, 2025

Announcement on Shareholding Reduction Plan for Shareholders Holding Over 5% Shares, Partial Directors and Senior Management Members

August 22, 2025

Announcement on Convening the 2025 Semi-annual Performance Briefing

August 21, 2025

2025 Semi-annual Report

August 14, 2025

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Ganirelix Injection

July 22, 2025

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Exenatide Injection

June 30, 2025

Announcement on Voluntary Disclosure of 2025 Semi-annual Earnings Preannouncement

June 19, 2025

Announcement on Implementation of Dividend Distribution for 2024

June 8, 2025

Announcement on Resolution of the 2024 Annual General Meeting

May 15, 2025

Report for Q1 2025

April 24, 2025

Announcement on Voluntary Disclosure of Earnings Preannouncement for Q1 2025

March 30, 2025

Announcement on Preliminary Earnings Estimate for 2024

February 27, 2025